Shanghai Gynecologic Oncology Group clinical trials
Shanghai Gynecologic Oncology Group is the lead sponsor of 9 current clinical trials in our China and South Korea registers. 3 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Bevacizumab, Gemox and Niraparib. The most-studied condition is Primary Peritoneal Carcinoma.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Shanghai Gynecologic Oncology Group
9 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
NCT03983226 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Drug: Niraparib |
Phase 2 | Recruiting | 2019-10 | China |
|
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
NCT05236686 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Not applicable | Recruiting | 2022-02 | China |
|
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
NCT05200260 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Drugs: Bevacizumab, Olaparib |
Phase 2 | Recruiting | 2022-07 | China |
|
Surgery for Relapsed Ovarian Cancer in Precision
NCT06602063 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Drug: Gemox |
Phase 1/2 | Not yet open | 2025-07 | China |
|
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NCT07674615 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary
Drug: Sacituzumab Govitecan |
Phase 1 | Not yet open | 2026-07 | China |
|
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
NCT04515602 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Phase 3 | Not yet open | 2021-01 | China |
|
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
NCT06846424 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
|
Phase 1 | Not yet open | 2025-06 | China |
|
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
NCT02859038 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
|
Phase 3 | Active, closed | 2016-08 | China, South Korea |
|
O-RADS MRI System on Early Detection of Ovarian Cancer
NCT07009743 · ClinicalTrials.gov ↗ · Ovarian Cancer (OvCa), Ovarian Cancer Metastatic
|
Observational | Active, closed | 2025-01 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Shanghai Gynecologic Oncology Group trials
5 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Shanghai Gynecologic Oncology Group trials
11 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 3 |
| Clinical trials in South Korea | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Primary Peritoneal Carcinoma
| Sponsor | Trials |
|---|---|
| North Eastern German Society of Gynaecological Oncology | 2 |
Sponsors with the most current trials registered for this condition.
Questions about Shanghai Gynecologic Oncology Group trials
How many clinical trials does Shanghai Gynecologic Oncology Group sponsor?
Shanghai Gynecologic Oncology Group is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China and South Korea registers, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Shanghai Gynecologic Oncology Group trials recruiting?
Yes. 3 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Shanghai Gynecologic Oncology Group testing?
Its current trials name 5 drugs and biologicals as interventions. The most frequent are Bevacizumab (1), Gemox (1), Niraparib (1), Olaparib (1) and Sacituzumab Govitecan (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.